FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240717116> ?p ?o ?g. }

• W4240717116 abstract "Abstract Background Hypofractionated radiotherapy is the current standard for adjuvant radiotherapy across many centres. Further hypofractionation may be possible but remains to be investigated in non-caucasian populations with more advanced disease, with a higher proportion of patients requiring mastectomy as well as tumour bed boost. We are reporting the design of randomized controlled trial testing the hypothesis that a one week (5 fractions) regimen of radiotherapy will be non-inferior to a standard three week (15 fractions) schedule. Methods We describe a multicenter, randomized controlled trial recruiting patients at large academic centres across India. Patients without distant metastases who merit adjuvant radiotherapy will be eligible for inclusion in the study. Patients in the control arm will receive adjuvant radiotherapy to the breast or chest wall (with/without regional nodes) to a dose of 40 Gy / 15 fractions / 3 weeks, while those in the experimental arm will receive a dose of 26 Gy / 5 fractions / 1 week (to the same volume). Use of a simultaneous integrated boost (dose of 8 Gy and 6 Gy respectively) is allowed in patients who have undergone breast conservation. A sample size of 2100 patients provides an 80% power to detect a non-inferiority of 3% in the 5-year locoregional recurrence rate with a one-sided type I error of 2.5%, assuming that the locoregional recurrence rate in the control arm is 5% at 5 years (corresponding to a hazard ratio of 1.63). Patients will be recruited over a period of 5 years, and followed up for a further 5 years thereafter. Discussion If a five-fraction regimen of breast cancer is proven to be non-inferior, this will result in a significant improvement in the access to radiotherapy, as well as reduced costs of treatment. The trial gives an opportunity to standardize and quality assure radiotherapy practices across the nation at the same time. Along with the results of the FAST Forward trial, the safety of this intervention in advanced node-positive disease requiring regional nodal radiation will be established. Trial Registration The trial has been registered at the Clinical Trial Registry of India (CTRI) vide registration number: CTRI/2018/12/016816 (31/12/2018) as well as the clinical trial.gov website at NCT03788213 (28/12/2018)." @default.
• W4240717116 created "2022-05-12" @default.
• W4240717116 creator A5025989792 @default.
• W4240717116 creator A5065101032 @default.
• W4240717116 creator A5085420736 @default.
• W4240717116 date "2020-06-16" @default.
• W4240717116 modified "2023-09-29" @default.
• W4240717116 title "HYPOfractionated Radiation Therapy Comparing A Standard Radiotherapy Schedule (Over Three Weeks) with A Novel One Week Schedule in Adjuvant Breast Cancer: An Open-Label Randomised Controlled Study (HYPORT- Adjuvant): Study Protocol for a Multicenter, Randomized Phase III Trial." @default.
• W4240717116 doi "https://doi.org/10.21203/rs.3.rs-32715/v1" @default.
• W4240717116 hasPublicationYear "2020" @default.
• W4240717116 type Work @default.
• W4240717116 citedByCount "0" @default.
• W4240717116 crossrefType "posted-content" @default.
• W4240717116 hasAuthorship W4240717116A5025989792 @default.
• W4240717116 hasAuthorship W4240717116A5065101032 @default.
• W4240717116 hasAuthorship W4240717116A5085420736 @default.
• W4240717116 hasBestOaLocation W42407171161 @default.
• W4240717116 hasConcept C121608353 @default.
• W4240717116 hasConcept C126322002 @default.
• W4240717116 hasConcept C141071460 @default.
• W4240717116 hasConcept C143998085 @default.
• W4240717116 hasConcept C155806632 @default.
• W4240717116 hasConcept C168563851 @default.
• W4240717116 hasConcept C207103383 @default.
• W4240717116 hasConcept C2777757722 @default.
• W4240717116 hasConcept C2777863537 @default.
• W4240717116 hasConcept C2781413609 @default.
• W4240717116 hasConcept C44249647 @default.
• W4240717116 hasConcept C509974204 @default.
• W4240717116 hasConcept C530470458 @default.
• W4240717116 hasConcept C71924100 @default.
• W4240717116 hasConceptScore W4240717116C121608353 @default.
• W4240717116 hasConceptScore W4240717116C126322002 @default.
• W4240717116 hasConceptScore W4240717116C141071460 @default.
• W4240717116 hasConceptScore W4240717116C143998085 @default.
• W4240717116 hasConceptScore W4240717116C155806632 @default.
• W4240717116 hasConceptScore W4240717116C168563851 @default.
• W4240717116 hasConceptScore W4240717116C207103383 @default.
• W4240717116 hasConceptScore W4240717116C2777757722 @default.
• W4240717116 hasConceptScore W4240717116C2777863537 @default.
• W4240717116 hasConceptScore W4240717116C2781413609 @default.
• W4240717116 hasConceptScore W4240717116C44249647 @default.
• W4240717116 hasConceptScore W4240717116C509974204 @default.
• W4240717116 hasConceptScore W4240717116C530470458 @default.
• W4240717116 hasConceptScore W4240717116C71924100 @default.
• W4240717116 hasLocation W42407171161 @default.
• W4240717116 hasLocation W42407171162 @default.
• W4240717116 hasLocation W42407171163 @default.
• W4240717116 hasOpenAccess W4240717116 @default.
• W4240717116 hasPrimaryLocation W42407171161 @default.
• W4240717116 hasRelatedWork W10346730 @default.
• W4240717116 hasRelatedWork W13747749 @default.
• W4240717116 hasRelatedWork W15609305 @default.
• W4240717116 hasRelatedWork W22000592 @default.
• W4240717116 hasRelatedWork W22284638 @default.
• W4240717116 hasRelatedWork W4133181 @default.
• W4240717116 hasRelatedWork W4274565 @default.
• W4240717116 hasRelatedWork W7038429 @default.
• W4240717116 hasRelatedWork W806154 @default.
• W4240717116 hasRelatedWork W992274 @default.
• W4240717116 isParatext "false" @default.
• W4240717116 isRetracted "false" @default.
• W4240717116 workType "article" @default.